ArticleCell cycle (Georgetown, Tex.)2016

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.

Hina Mir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.